Advances in Radiotracer Development for Molecular Imaging

Liu, Yongjian

doi:10.1007/978-1-4939-0894-3_9

Cited by 1 publication

(1 citation statement)

References 276 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this context, key characteristics of the imaging agent include high affinity for the molecular target, the ability to overcome biological barriers, low toxicity, efficient clearance in vivo , straightforward production [23, 24], and high specific activity for radioactive probes which is defined as radioactivity per mass unit of radionuclide or radiolabeled compound [25]. The number of targets and the affinity of the imaging agent to these targets play an important role in its effectiveness because the presence of non-radioactive components may compete with the radiolabeled compound by binding to the target and decreasing signal uptake in the tissue [26].…”

Section: Radionuclidesmentioning

confidence: 99%

Recent Advances of Radionuclide-Based Molecular Imaging of Atherosclerosis

Kazuma¹,

Sultan²,

Zhao³

et al. 2015

CPD

Self Cite

View full text Add to dashboard Cite

Atherosclerosis is a systemic disease characterized by the development of multifocal plaque lesions within vessel walls and extending into the vascular lumen. The disease takes decades to develop symptomatic lesions, affording opportunities for accurate detection of plaque progression, analysis of risk factors responsible for clinical events, and planning personalized treatment. Of the available molecular imaging modalities, radionuclide-based imaging strategies have been favored due to their sensitivity, quantitative detection and pathways for translational research. This review summarizes recent advances of radiolabeled small molecules, peptides, antibodies and nanoparticles for atherosclerotic plaque imaging during disease progression.

show abstract